-
公开(公告)号：US11229638B2
公开(公告)日：2022-01-25
申请号：US16641166
申请日：2018-08-20
发明人： Mark J. Bartlett , Britton Kenneth Corkey , Jennifer Leigh Cosman , Kristyna M. Elbel , Elfatih Elzein , Rao V. Kalla , Dmitry Koltun , Xiaofen Li , Eric Q. Parkhill , Thao Perry
IPC分类号： C07D471/04 , A61K31/437 , A61K31/4745 , C07D487/04 , A61P35/00 , A61K31/497 , A61K35/17 , A61K31/4985 , A61K31/5025 , A61K31/506 , A61K31/519 , A61K35/26 , A61K39/395 , A61K45/06 , C07K16/28
摘要： Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed:
-
公开(公告)号：US20200316035A1
公开(公告)日：2020-10-08
申请号：US16641166
申请日：2018-08-20
发明人： Mark J. Bartlett , Britton Kenneth Corkey , Jennifer Leigh Cosman , Kristyna M. Elbel , Elfatih Elzein , Rao V. Kalla , Dmitry Koltun , Xiaofen Li , Eric Q. Parkhill , Thao Perry
IPC分类号： A61K31/437 , A61K39/395 , A61K31/519 , A61K35/17 , C07D471/04 , A61K31/506 , A61K31/497 , A61K31/5025 , C07D487/04 , A61K31/4985
摘要： Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed:
-
公开(公告)号：US11098027B2
公开(公告)日：2021-08-24
申请号：US16502453
申请日：2019-07-03
发明人： Mark J. Bartlett , Britton Kenneth Corkey , Jennifer Leigh Cosman , Elfatih Elzein , Xiaofen Li
IPC分类号： C07D401/14 , C07D403/04 , C07D401/04 , C07D413/04 , C07D209/34 , C07D263/58 , A61K31/519
摘要： Compounds having the following Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use and preparation are disclosed:
-
公开(公告)号：US20160333009A1
公开(公告)日：2016-11-17
申请号：US15153527
申请日：2016-05-12
发明人： Mark J. Bartlett , Julian Andrew Codelli , Britton Kenneth Corkey , Jennifer Leigh Cosman , Kristyna Elbel , Jennifer Alissa Loyer-Drew , David Sperandio , Joshua Van Veldhuizen , Hai Yang , Suet Chung Yeung
IPC分类号： C07D471/04 , C07D235/08 , A61K31/4184 , A61K31/5377 , C07D401/12 , A61K31/454 , A61K31/437 , A61K31/506 , A61K31/497 , A61K31/55 , A61K31/541 , A61K31/439 , C07D405/12 , C07D405/14 , C07D471/08 , A61K31/553 , C07D235/30 , C07D235/14 , C07D401/04 , C07D235/12 , A61K31/444 , A61K31/4545 , A61K31/538 , A61K31/5386 , A61K31/438 , C07D403/12 , A61K31/4439 , C07D235/24 , C07D413/12 , A61K31/496 , C07D487/04 , A61K31/4725 , C07D235/28 , A61K45/06
CPC分类号： C07D471/04 , A61K31/4184 , A61K31/437 , A61K31/438 , A61K31/439 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , C07D235/06 , C07D235/08 , C07D235/12 , C07D235/14 , C07D235/16 , C07D235/24 , C07D235/28 , C07D235/30 , C07D295/125 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D471/08 , C07D487/04
摘要： The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R1, R2a, R2b, Rn, Rm, and Rt are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.
摘要翻译： 或其药学上可接受的盐，其中X，L，n，m，R1，R2a，R2b，Rn，Rm和Rt如本文所定义，以及包含式I化合物或其药学上可接受的盐的药物组合物 以及使用其来治疗由IDO1介导的病症的方法。
-
公开(公告)号：US11040033B2
公开(公告)日：2021-06-22
申请号：US15999548
申请日：2018-08-20
发明人： Mark J. Bartlett , Britton Kenneth Corkey , Jennifer Leigh Cosman , Kristyna M. Elbel , Elfatih Elzein , Rao V. Kalla , Dmitry Koltun , Xiaofen Li , Eric Q. Parkhill , Thao Perry
IPC分类号： A61K31/4745 , A61P35/00 , A61K31/497 , A61K31/4985 , A61K31/5025 , A61K31/506 , A61K31/519 , A61K35/17 , A61K35/26 , A61K45/06 , C07D471/04 , C07D487/04 , A61K31/437 , A61K39/395 , C07K16/28
摘要： Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed:
-
公开(公告)号：US20200031801A1
公开(公告)日：2020-01-30
申请号：US16502453
申请日：2019-07-03
发明人： Mark J. Bartlett , Britton Kenneth Corkey , Jennifer Leigh Cosman , Elfatih Elzein , Xiaofen Li
IPC分类号： C07D401/14 , C07D403/04 , C07D401/04 , C07D413/04 , C07D209/34 , C07D263/58
摘要： Compounds having the following Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use and preparation are disclosed:
-
公开(公告)号：US20190192504A1
公开(公告)日：2019-06-27
申请号：US15999548
申请日：2018-08-20
发明人： Mark J. Bartlett , Britton Kenneth Corkey , Jennifer Leigh Cosman , Kristyna M, Elbel , Elfatih Elzein , Rao V. Kalla , Dmitry Koltun , Xiaofen Li , Eric Q Parkhill , Thao Perry
IPC分类号： A61K31/4745 , A61K31/5025 , A61K31/4985 , A61K31/506 , A61K45/06 , C07K16/28 , A61K39/395 , A61K31/519 , A61K35/26 , C07D471/04
CPC分类号： A61K31/4745 , A61K31/4985 , A61K31/5025 , A61K31/506 , A61K31/519 , A61K35/26 , A61K39/3955 , A61K45/06 , A61P35/00 , C07D471/04 , C07D487/04 , C07K16/2827 , C07K2317/24
摘要： Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed:
-
公开(公告)号：US09951065B2
公开(公告)日：2018-04-24
申请号：US15153527
申请日：2016-05-12
发明人： Mark J. Bartlett , Julian Andrew Codelli , Britton Kenneth Corkey , Jennifer Leigh Cosman , Kristyna Elbel , Jennifer Alissa Loyer-Drew , David Sperandio , Joshua Van Veldhuizen , Hai Yang , Suet Chung Yeung
IPC分类号： C07D235/06 , C07D235/24 , C07D295/125 , C07D401/12 , C07D471/04 , A61K45/06 , C07D235/08 , A61K31/4184 , A61K31/5377 , A61K31/454 , A61K31/437 , A61K31/506 , A61K31/497 , A61K31/55 , A61K31/541 , A61K31/439 , C07D405/12 , C07D405/14 , C07D471/08 , A61K31/553 , C07D235/30 , C07D235/14 , C07D401/04 , C07D235/12 , A61K31/444 , A61K31/4545 , A61K31/538 , A61K31/5386 , A61K31/438 , C07D403/12 , A61K31/4439 , C07D413/12 , A61K31/496 , C07D487/04 , A61K31/4725 , C07D235/28 , C07D235/16 , C07D409/12
CPC分类号： C07D471/04 , A61K31/4184 , A61K31/437 , A61K31/438 , A61K31/439 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , C07D235/06 , C07D235/08 , C07D235/12 , C07D235/14 , C07D235/16 , C07D235/24 , C07D235/28 , C07D235/30 , C07D295/125 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D471/08 , C07D487/04
摘要： The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R1, R2a, R2b, Rn, Rm, and Rt are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.042 秒)
